A
randomized controlled multi-centre clinical trial was conducted for evaluating the efficacy and safety of latamoxef(LMOX)compared
with
cefoperazone(CPZ)in the treatment of 202 cases of bacterial infections including 133 cases of lower respiratory tract infections,60 cases of surgical infections and 9 cases of UTI.Each group involved in 101 cases,Both the test compound and the control were given intravenously,the dosage was1-2 g every 12 hours for10-14 days.The daily dosage should not exceed 4 g.The results showed that LMOX with cure rate 70.3% was more effective than that of CPZ(cure rate 57.4%)(P<0.05).The overall efficacy rate of LMOX and CPZ were 91.1% and 81 9% rexpectively(P>0.05).The clearance rate were 86.8% and 77.3% respectively(P>0.05)without statistical significant difference.93.7% of the total 224 strains isolated from patients were sensitive to LMOX.The MIC50 of LMOX against E. coli,Kl.pneumoniae,Ent.cloacae,Acinetobacter spp.and B fragilis was 0.125一2mg/l.The incidence of adverse reaction of LMOX was 5.9% significantly lower than that of CPZ 10.9%,(P<0.05).There were no abnormal changes of CT,BT,and platelet count of both group.No bleeding reaction was found during and after the therapy,The above results indicated that the oxacephem LMOX was safe and highly effective against aerobic and anaerobic bacterial infections when applied according to this thertqoeutic regimen.